期刊
MOLECULAR CELL
卷 42, 期 1, 页码 36-49出版社
CELL PRESS
DOI: 10.1016/j.molcel.2011.02.020
关键词
-
资金
- CR-UK [C10652/A10250]
- NIH [R01GM062281]
- Scottish Executive Chief Scientist Office (CSO)
- Think Pink Scotland
- Cancer Research UK [12481] Funding Source: researchfish
- Chief Scientist Office [CAF/06/24] Funding Source: researchfish
Mutations in both RAS and the PTEN/PIK3CA/AKT signaling module are found in the same human tumors. PIK3CA and AKT are downstream effectors of RAS, and the selective advantage conferred by mutation of two genes in the same pathway is unclear. Based on a comparative molecular analysis, we show that activated PIK3CA/AKT is a weaker inducer of senescence than is activated RAS. Moreover, concurrent activation of RAS and PIK3CA/AKT impairs RAS-induced senescence. In vivo, bypass of RAS-induced senescence by activated PIK3CA/AKT correlates with accelerated tumorigenesis. Thus, not all oncogenes are equally potent inducers of senescence, and, paradoxically, a weak inducer of senescence (PIK3CA/AKT) can be dominant over a strong inducer of senescence (RAS). For tumor growth, one selective advantage of concurrent mutation of RAS and PTEN/PIK3CA/AKT is suppression of RAS-induced senescence. Evidence is presented that this new understanding can be exploited in rational development and targeted application of prosenescence cancer therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据